Date/Time
Date(s) - Tue 04/28/2015
12:00 pm - 1:15 pm
Location
Hanson Bridgett LLP
Claim Construction after Teva Pharmaceuticals
Click here to register.
With its decision on January 20, 2015 in Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., the Supreme Court changed the law of claim construction, holding that the Federal Circuit must apply a “clear error,” not a de novo, standard of review, when reviewing a district court’s resolution of subsidiary factual matters made in the course of its construction of a patent claim.
In this presentation, two experienced patent litigators, Michael Carlson and Robert McFarlane will share their insights into how the Teva decision is changing patent litigation.
Presenters:
Michael M. Carlson is a partner at Schnader Harrison experienced in many areas of commercial litigation, with particular expertise in intellectual property litigation. He has federal and state trial experience in both civil and criminal matters, has argued cases before the U.S. Court of Appeals for the Federal Circuit and several districts of the California Court of Appeal, and has been involved in appeals before the U.S. Court of Appeals for the Ninth Circuit and the California Supreme Court. Mr. Carlson is chair of Schnader’s Intellectual Property Litigation Practice Group, and is also the president of the San Francisco Intellectual Property Law Association (SFIPLA).

Location:
Hanson Bridgett LLP, 425 Market, 26th Floor, San Francisco, 94105
Price and Registration:
Ticket Type | Price (Before Ticketing Fees) |
---|---|
In-Person In-House Counsel | Free |
In-Person SFIPLA Member (Law Firm) | $35 |
In-Person Non-Member | $40 |
Student | $10 |
Click here to register and pay on-line, or mail your RSVP, desired ticket type, and check made payable to SFIPLA to us at the address on our contact page.
 Categories